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Arenaviruses and hantaviruses cause severe human
disease. Little is known regarding host proteins
required for their propagation. We identified
human proteins that interact with the glyco-
proteins (GPs) of a prototypic arenavirus and
hantavirus and show that the lectin endoplasmic
reticulum (ER)-Golgi intermediate compartment
53 kDa protein (ERGIC-53), a cargo receptor
required for glycoprotein trafficking within the early
exocytic pathway, associates with arenavirus,
hantavirus, coronavirus, orthomyxovirus, and filovi-
rus GPs. ERGIC-53 binds to arenavirus GPs
through a lectin-independent mechanism, traffics
to arenavirus budding sites, and is incorporated
into virions. ERGIC-53 is required for arenavirus,
coronavirus, and filovirus propagation; in its
absence, GP-containing virus particles form but
are noninfectious, due in part to their inability to
attach to host cells. Thus, we have identified a
class of pathogen-derived ERGIC-53 ligands, a
lectin-independent basis for their association with
ERGIC-53, and a role for ERGIC-53 in the pro-
pagation of several highly pathogenic RNA virus
families.
INTRODUCTION
Arenaviruses and hantaviruses are rodent-borne, negative-
sense RNA viruses that cause significant morbidity and mortal-522 Cell Host & Microbe 14, 522–534, November 13, 2013 ª2013 Elsity in humans (Buchmeier et al., 2007; Schmaljohn and Nichol,
2007). Most pathogenic arenaviruses are associated with
severe hemorrhagic fever syndromes in humans. Examples
include the New World arenaviruses Junin virus (JUNV),
Machupo virus (MACV), and Guanarito virus (GTOV), which
are the etiologic agents of Argentine, Bolivian, and Venezuelan
hemorrhagic fevers, respectively, as well as Lassa virus
(LASV), an Old World arenavirus that causes Lassa fever along
the coast of West Africa (Buchmeier et al., 2007). Additionally,
lymphocytic choriomeningitis virus (LCMV) can cause aseptic
meningitis in immunocompetent individuals and is a potent
teratogen (Buchmeier et al., 2007). LCMV and Dandenong virus
(DANV), an LCMV-like virus, are also responsible for a nearly
uniform lethality in immunosuppressed recipients of virus-
infected tissues (Fischer et al., 2006; Palacios et al., 2008). Han-
taviruses cause two human illnesses: hemorrhagic fever with
renal syndrome in the Old World and hantavirus cardiopulmo-
nary syndrome (HCPS) in the New World (Schmaljohn and
Nichol, 2007). Sin Nombre virus (SNV) and Andes virus (ANDV)
are the primary etiologic agents of HCPS in North and South
America, respectively, and are associated with a fatality rate
of 35%–39% (da Rosa Elkhoury et al., 2012; MacNeil et al.,
2011). US Food and Drug Administration (FDA)-approved vac-
cines or effective antivirals do not currently exist for the preven-
tion and/or therapeutic treatment of arenavirus or hantavirus
disease.
Arenaviruses and hantaviruses each encode an envelope
glycoprotein (GP) that decorates the surface of the virion and
functions to mediate attachment and entry of virions into permis-
sive host cells. Each GP is encoded as a precursor (GPC) that is
proteolytically processed into mature subunits. The arenavirus
GPC is posttranslationally modified to yield a stable signal pep-
tide (SSP) as well as GP1 and GP2 subunits (Lenz et al., 2001),
whereas the hantavirus GPC is cotranslationally processedevier Inc.
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GP subunits form a mature GP complex (SSP-GP1-GP2 for
arenaviruses; G1-G2 for hantaviruses) that facilitates receptor
binding and entry (Buchmeier et al., 2007; Schmaljohn and
Nichol, 2007).
Relatively little is known regarding interactions that arenavirus
or hantavirus GPs have with host proteins or the importance of
such interactions for viral replication and disease pathogenesis.
Herein, we utilized a proteomics approach to comprehensively
identify human proteins that interact with GPs encoded by
a prototypic arenavirus or hantavirus. We show that the
endoplasmic reticulum (ER)-Golgi intermediate compartment
53 kDa protein (ERGIC-53), an intracellular cargo receptor that
facilitates the anterograde transport of a limited number of
glycoprotein ligands in the early exocytic pathway (Appenzeller
et al., 1999), has a conserved interaction with GPs encoded by
multiple families of RNA viruses and is essential for the forma-
tion of infectious arenavirus, coronavirus, and filovirus particles
in a GP-specific manner. Our results suggest that loss of
ERGIC-53 or its functionality leads to the formation of
GP-containing virions that are defective in their ability to attach
to permissive host cells.
RESULTS
Identification of Cellular Proteins that Associate with
Arenavirus and Hantavirus GPs and Choice of ERGIC-53
To identify human proteins that associate with arenavirus and
hantavirus GPs, we used an approach that featured affinity
purification (AP) of biotinylated viral proteins (LCMV GP to
represent arenaviruses or ANDV GP for hantaviruses) in com-
plex with host proteins, followed by mass spectrometry to iden-
tify host protein partners as described in Figure S1A and the
Supplemental Experimental Procedures (available online). We
identified a number of host proteins that associated with
LCMV GP (n = 309), ANDV GP (n = 134), or both GPs (n = 51)
(Figures 1A–1C, S1B, and S1C; Tables S1A–S1C). As shown
in Figure S1D and Table S1D, host proteins that associated
with both GPs were enriched for processes involving the
ER, protein folding, and vesicular transport. The LCMV GP-
only partners were enriched for processes that included the
ER, the proteasome, and nuclear import, while the ANDV GP-
only partners were enriched for protein translation and ribo-
some biogenesis. We were particularly interested in the subset
of proteins that interacted with both GPs, as they could serve
as broad-spectrum antiviral targets. Of these, we chose
ERGIC-53 for further study based upon several criteria. First,
the ERGIC-53-viral GP interaction is physiologically plausible
(e.g., each protein traffics within the exocytic pathway);
ERGIC-53 is a mannose-specific lectin (Itin et al., 1996) and
the viral GPs are mannosylated (Schmaljohn et al., 1986; Wright
et al., 1990). Second, based on its identification as a cargo re-
ceptor within the exocytic pathway (Appenzeller et al., 1999),
we hypothesized that ERGIC-53 could be required for GP
maturation and therefore might be critical for viral propagation.
Finally, ERGIC-53 is an attractive target because loss of this
protein or its normal function is well tolerated both in vitro
(Mitrovic et al., 2008; Nyfeler et al., 2006; Vollenweider et al.,
1998) and in vivo (Khoriaty et al., 2012).Cell Host &Confirmation that ERGIC-53 Has a Conserved
Association with GPs Encoded by Multiple Pathogenic
Arenaviruses and Hantaviruses
We next wished to determine whether ERGIC-53 could asso-
ciate with additional GPs encoded by arenaviruses (LASV,
MACV, JUNV strain XJ, JUNV strain Candid #1 [C#1], andWhite-
water Arroyo virus [WWAV]) or hantaviruses (SNV). Each viral GP
tested, when serving as bait, was able to coprecipitate ERGIC-
53 (Figures 1D, 1F–1H, S1E, and data not shown). Likewise,
ERGIC-53 was able to coprecipitate each GP screened (Figures
1E, 1I–1K, S1F–S1I, and data not shown). For the arenavirus
GPs, only the full-length GPC was coprecipitated as prey. A
full-length hantavirus GPC cannot be recovered, as this protein
is cotranslationally cleaved into G1 and G2 subunits prior
to synthesis of a full-length GPC species (Lo¨ber et al., 2001).
As shown in Figure 1L, we further verified the specificity of the
ERGIC-53-JUNV C#1 GP interaction by showing that both pro-
teins strongly colocalize within a structure that we putatively
identify as the ERGIC; both proteins also preferentially concen-
trate in this structure.
ERGIC-53 Is Required for Arenavirus Propagation
We conducted a series of viral challenge studies to determine
how various manipulations of ERGIC-53 might impact the ability
of arenaviruses (JUNV C#1 or DANV) to release infectious
progeny. Partial silencing of ERGIC-53 expression via siRNA
transfection led to a considerable reduction in the release of
infectious JUNV C#1 (24 hr postinfection [pi], 39.6% decrease,
p = 0.03; 48 hr pi, 64% decrease, p = 0.02; 72 hr pi, 51%
decrease, p = 0.01) (Figures 2A and S2A), whereas increased
expression of WT ERGIC-53 enhanced release of infectious
JUNV C#1 (24 hr pi, 48% increase, p = 0.025; 48 hr pi, 68%
increase, p = 0.004) (Figures 2B and S2B). Expression of an
ER-restricted, dominant-negative (DN) mutant of ERGIC-53
(Vollenweider et al., 1998) resulted in a pronounced reduction
in the release of infectious JUNV C#1 (48 hr pi, 90.5% decrease,
p = 1.4 3108; 72 hr pi, 99.8% decrease, p = 3.2 3 104) (Fig-
ures 2C and S2C), DANV (95% reduction, p = 0.003) (Figures 2D
and S2D), and LCMV strain Armstrong 53b (data not shown).
These experiments clearly demonstrate that ERGIC-53 is
required for the propagation of New World and Old World
arenaviruses.
The Release of Infectious JUNV C#1 Is Restricted in Cell
Lines Derived from ERGIC-53 Null Individuals
Humans with homozygous null mutations in LMAN1 (lectin,
mannose binding 1), the gene encoding ERGIC-53, have com-
bined deficiency of factor V (FV) and FVIII (F5F8D, Online
Mendelian Inheritance in Man [OMIM] 227300), a mild bleeding
disorder characterized by reduced levels of circulating FV and
FVIII (Nichols et al., 1998). We therefore conducted challenge
studies featuring B cells derived from LMAN1+/+ (2829-D)
and LMAN1/ (CRC-78 and CRC-79) individuals. The two
LMAN1/ individuals, despite being from separate families
(A2 and A12 in Neerman-Arbez et al., 1999), encode an identical
null mutation (c.822-1G > A splice site mutation) that abrogates
expression of ERGIC-53. Significantly less infectious virus was
released from each of the LMAN1/ cell lines when compared
to the LMAN1+/+ control cells (96% and 97% decrease forMicrobe 14, 522–534, November 13, 2013 ª2013 Elsevier Inc. 523
Figure 1. Identification of Human Proteins that Associate with Arenavirus and Hantavirus GPs
(A and B) HEK293T cells were cotransfected with a pCAGGS plasmid encoding either LCMVGP (A) or ANDV GP (B) with a C-terminal HA epitope tag and a biotin
acceptor peptide (BAP), along with a second plasmid that encodes BirA, a bacterial biotin ligase, to ensure biotinylation of the viral GPs. As a control, cells were
(legend continued on next page)
Cell Host & Microbe
ERGIC-53 Is Required for Virion Infectivity
524 Cell Host & Microbe 14, 522–534, November 13, 2013 ª2013 Elsevier Inc.
Cell Host & Microbe
ERGIC-53 Is Required for Virion InfectivityCRC-78 and CRC-79, respectively; p < 0.0001 for each) (Figures
2E and S2E).
ERGIC-53’s Influence on JUNV Replication Is Specific
and Can Be Minimally Mapped to the JUNV GP
To determine the specificity of ERGIC-53’s impact on arenavirus
replication, we employed a pseudotyping approach, featuring
vesicular stomatitis virus (VSV) strain DG, a recombinant VSV
that does not encode its native glycoprotein (G) and accordingly
cannot form infectious particles unless a suitable viral glycopro-
tein (e.g., VSV G or JUNV GP) is provided in trans (Whitt, 2010).
There was no difference in the formation of infectious VSVDG
particles decorated with native VSV G between the WT and DN
ERGIC-53 backgrounds (Figures 3A and S3A). This may be due
to the fact that VSVG does not associate with ERGIC-53 in coim-
munoprecipitation assays (Figures 3E and 3F). The formation of
infectious VSVDG decorated with JUNV XJ GP was significantly
impaired in cells expressing DN ERGIC-53 compared to the WT
ERGIC-53 cells (80% reduction; p = 0.001) (Figures 3B and
S3B). These experiments demonstrate that ERGIC-53’s impact
on arenavirus propagation is specific and can be minimally
restricted to the GP itself. Importantly, the fact that ERGIC-53
does not associate with VSV G demonstrates the specificity of
its interaction with arenavirus and hantavirus GPs.
ERGIC-53 Broadly Associates with Viral Class I Fusion
Proteins and Is Required for the Propagation of
Coronaviruses and Filoviruses
We next screened for an association between ERGIC-53 and
class I fusion GPs encoded by coronaviruses (the severe acute
respiratory syndrome coronavirus [SARS CoV] spike protein [S]),
orthomyxoviruses (theH1N1 influenzavirusA/WSN/33hemagglu-
tinin protein [HA]), and filoviruses (the Ebola [EBOV] and Marburg
virus [MARV] GPs). Each GP, when used as bait, was able to
coprecipitate ERGIC-53 (Figures 3G and 3I). Reciprocally,
ERGIC-53 was able to coprecipitate the uncleaved, precursor
GPfromeachvirus (Figures3Hand3J). The formationof infectious
VSVDG particles decorated with either the SARS CoV S or EBOV
GP was significantly impaired in cells expressing DN ERGIC-53
compared to the WT ERGIC-53 cells (81% reduction, p = 0.03
for SARS CoV; 70% reduction, p = 0.0002 for EBOV) (Figurescotransfected with the BirA plasmid and an empty vector. Biotinylated GPs and a
magnetic streptavidin beads and separated on polyacrylamide gels for western b
for LCMV; G1 andG2 for ANDV) and Coomassie staining formass spectrometry an
digestion, and mass spectrometry analysis, as described in the Supplemental E
S1B and S1C for cut maps, Tables S1A–S1C for a list of the proteins, and Table
(C) Venn diagram representing the number of identified host proteins associated
(D–G, I, and J) ERGIC-53 has a conserved association with arenavirus and hanta
either ANDVGP or SNVGP (D); ANDVGP (E); LASVGP, LCMVGP, or JUNV XJGP
(J) with a C-terminal HA epitope tag and a BAP or, as a control, an empty pCAGGs
ensure biotinylation of eachGP. Viral GPs (D, F, andG) or ERGIC-53 (E, I, and J) we
Input lysates and purified bead fractions were screened for ERGIC-53 (D, F, and G
and J) as prey via western blot. See Figures S1E–S1I for screening of additional
(H and K) HEK293T (H) or Vero E6 (K) cells were infected with JUNV C#1 and JU
lysates and purified bead fractions were screened for ERGIC-53 (H) or JUNV C#
(L) ERGIC-53 and JUNV C#1 GP concentrate in the same intracellular structure.
JUNV C#1 GP (green) and ERGIC-53 (red). Colocalization between GP and ERG
shows background gating (white lines) and specific immunofluorescence signal f
(region 3) (78.6% of ERGIC-53 signal colocalized with GP signal; 52.2% of GP s
Cell Host &3C, 3D, S3C, and S3D). In summary, ERGIC-53 has a conserved
interactionwith class I fusionGPs and is required for the propaga-
tion of coronaviruses and filoviruses in a GP-specific manner.
Trafficking of JUNV C#1 GP or hTfR1 to the Plasma
Membrane Is Not Influenced by ERGIC-53
To determine how the loss of ERGIC-53 function impaired
the formation of infectious arenavirus particles, we first tested
whether ERGIC-53 could be a bona fide cargo receptor required
for the proper anterograde trafficking of JUNV GP (Appenzeller
et al., 1999). Cells expressingWT or DN ERGIC-53 were infected
with JUNV C#1 and screened for surface expression of JUNV
C#1 GP. Interestingly, GP surface staining was equivalent in
both the WT and DN ERGIC-53 transfected cells in terms of
the frequency of cells with GP expression (46% WT versus
47% DN) as well as the intensity of GP staining (median fluores-
cence intensity [MFI] of 348 forWT versus 363 for DN) (Figure 4B).
Confocal microscopy analysis revealed a similar result (Fig-
ure 4A). The DN ERGIC-53 had no impact on the ability of
hTfR1, the surface receptor required for GP-mediated JUNV en-
try into host cells (Radoshitzky et al., 2007), to traffic to the cell
surface (Figure S4). In summary, cells expressing DN ERGIC-
53 have normal surface expression of hTfR1, manifest no defect
in viral entry of WT JUNV C#1 particles, and display no defect for
GP synthesis or its trafficking to the plasma membrane.
The DN ERGIC-53 Mutant Does Not Impair Proteolytic
Processing of JUNV GPC or the Incorporation of GP
Species into Virus-like Particles
Cells expressingWTorDNERGIC-53were transfectedwith plas-
mids encoding the JUNV matrix protein (Z) and JUNV XJ GP to
allow for virus-like particle (VLP) formation and release. Expres-
sion of DN ERGIC-53 did not impair the generation of GP2 from
GPC in cells or the incorporation of GP2 into VLPs (Figure 4C).
Loss of ERGIC-53 Leads to the Formation of Virus
Particles that Are Noninfectious
In Figures 2E and S2E, we show that JUNV C#1 is impaired
in its ability to release infectious progeny from LMAN1/ cells.
To determine whether this was due to (i) a general deficiency
in JUNV C#1 particle release or (ii) the release of defectivessociated host proteins were affinity purified (AP) from cell lysates (input) using
lot analysis to verify purification of the various GP species (GPC, GP1, and GP2
alysis. Each Coomassie-stained gel lanewas cut into sections for in-gel, tryptic
xperimental Procedures (see Figure S1A for the proteomics workflow, Figures
S1D and Figure S1D for results of a functional clustering analysis).
with LCMV GP, ANDV GP, or both GPs.
virus GPs. HEK293T cells were transfected with a pCAGGS plasmid encoding
(F); JUNVC#1GP (G); LASVGP, LCMVGP, or JUNV XJGP (I); or JUNVC#1GP
plasmid. In (D), (F), and (G), cells were also transfected with the BirA plasmid to
re affinity purified or immunoprecipitated, respectively, as bait from cell lysates.
) or viral GP species (G2 for hantaviruses; GPC and GP2 for arenaviruses) (E, I,
GPs.
NV GP (H), or ERGIC-53 (K) was immunoprecipitated from cell lysates. Input
1 GP species (GPC and GP1) (K) as prey via western blot.
JUNV C#1-infected HEK293T cells were fixed, permeabilized, and stained for
IC-53 is displayed as white pixels in the colocalization mask. The histogram
or JUNV GP (region 1), ERGIC-53 (region 2), or colocalized GP and ERGIC-53
ignal colocalized with ERGIC-53 signal). Scale bar = 20 mm.
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Figure 2. ERGIC-53 Is Required for Arenavirus Propagation
(A) Silencing ERGIC-53 expression impairs the release of infectious JUNVC#1. HEK293T cells were transfectedwith an ERGIC-53-specific siRNA or a scrambled,
negative control siRNA and challenged 72 hr later with JUNV C#1. Supernatants and cell protein lysates were screened for JUNV C#1 plaque-forming units (pfu)
via plaque assay and ERGIC-53 or calreticultin (CRT) via western blot. Data are presented as mean pfu ± SEM relative to the empty vector-transfected wells and
are the summation of two independent experiments (24 and 48 hr pi, n = 5, 72 hr n = 6).
(B) Overexpression of WT ERGIC-53 enhances infectious JUNV C#1 release. HEK293T cells were transfected with a plasmid encoding Myc-tagged, WT ERGIC-
53, or, as a control, an empty plasmid; 48 hr following transfection, these cells were challenged with JUNV C#1. Supernatants and cell protein lysates were
screened for JUNV C#1 pfu via plaque assay and Myc-ERGIC-53 or CRT via western blot. Data are presented as mean pfu ± SEM relative to the empty vector-
transfected wells and are the summation of two independent experiments (n = 6 at each time point).
(C and D) Restriction of ERGIC-53 to the ER impairs the release of infectious JUNVC#1 andDANV. HEK293T cells were transfected with a plasmid encodingMyc-
tagged DN ERGIC-53 or, as a control, an empty plasmid; 24 hr later, cells were challenged with JUNV C#1 (C) or DANV (D). Supernatants and cell protein lysates
were screened for pfu via plaque assay and Myc-DN ERGIC-53 or CRT via western blot. Data are presented as mean pfu ± SEM relative to the empty vector-
transfected wells and are representative of two independent experiments (n = 12 or n = 6 per experiment for JUNV C#1 or DANV, respectively).
(E) Release of infectious JUNVC#1 is impaired in ERGIC-53 (LMAN1/) null cells. EBV-transformed B cells from LMAN1+/+ (2829-D) and LMAN1/ (CRC-78 and
CRC-79) individuals were challenged with JUNV C#1. Supernatants and cell protein lysates were screened for JUNV C#1 pfu via plaque assay and ERGIC-53 or
actin via western blot. Data are presented as mean pfu ± SEM relative to the LMAN1+/+ cells and are representative of two independent experiments (n = 3 per
condition per experiment).
For (A)–(E), *p < 0.05, **p < 0.01, and ***p < 0.001, as determined using the unpaired Student’s t test. Note that western blot results from representative lysates are
shown; the full panel of lysates is displayed in Figure S2.
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LMAN1+/+ (2829-D) or LMAN1/ (CRC-78) cells and screened
them for infectious virus, viral genome, and viral structural
proteins. We found no discernible difference in the quantity of
viral proteins (GP1, nucleoprotein [NP], or Z) released from
LMAN1+/+ or LMAN1/ cells (Figure 4D), despite a nearly
10-fold reduction in infectious virus titer from LMAN1/ cells526 Cell Host & Microbe 14, 522–534, November 13, 2013 ª2013 Els(Figure 4E). Additionally, the LMAN1/-derived particles con-
tained viral genomic RNA with a 6.4-fold higher ratio of
genome to infectious virus compared to LMAN1+/+ particles
(Figure 4F). Lastly, the LMAN1/ particles also exhibited a
specific defect in attachment to host cells (52% reduction
compared to LMAN1+/+ particles) (Figure 4G). In summary,
loss of ERGIC-53 expression does not impact the ability ofevier Inc.
Figure 3. ERGIC-53 Broadly Associates with Class I Viral Fusion GPs and Influences the Propagation of JUNV, SARS CoV, and EBOV in a
GP-Specific Manner
(A–D) ERGIC-53 is required for the production of infectious viral particles in a GP-specific manner. HEK293T cells were initially transfected with a plasmid
encoding Myc-taggedWT or DN ERGIC-53, then 24 hr later with a plasmid encoding VSV G (A), JUNV XJ GP (B), SARS CoV S (C), or EBOV GP (D). Following the
final transfection (24 hr), cells were challenged with VSVDG. Supernatants and cell protein lysates were screened for infectious VSVDG particles pseudotyped
with the indicated viral GP via focus assay and Myc-ERGIC-53 (WT or DN) or CRT via western blot (see Figure S3 for blots), respectively. Data are presented as
mean infectious units ± SEM relative to the WT ERGIC-53 vector-transfected wells and are representative of two independent experiments (n = 3 wells per
condition per experiment). *p < 0.05, **p < 0.01, and ***p < 0.001, as determined using the unpaired Student’s t test.
(E and F) ERGIC-53 does not associate with VSV G. HEK293T cells were transfected with a plasmid encoding VSV G or an empty plasmid, and either VSV G (E) or
ERGIC-53 (F) was immunoprecipitated as bait from cell lysates (input). Immunoprecipitated bead fractions were screened for ERGIC-53 (E) or VSV G (F) as prey
via western blot.
(G–J) ERGIC-53 has a conserved association with class I viral fusion GPs. HEK293T cells were transfected with a plasmid encodingWTERGIC-53 and a pCAGGS
plasmid encoding either SARSCoV S (G andH) or influenza A/WSN/33HA, EBOVGP, orMARVGP (I and J) with a C-terminal HA epitope tag and BAP or an empty
pCAGGs plasmid. In (G) and (I), cells were also transfected with the BirA plasmid to ensure biotinylation of each GP. Viral GPs (G and I) or ERGIC-53 (H and J)
were affinity purified or immunoprecipitated, respectively, as bait from cell lysates. Input lysates and purified bead fractions were screened for ERGIC-53
(G and I) or viral GP species (full-length S and the processed S2 subunit for SARS CoV; full-length HA0 and the processed subunit HA2 for influenza virus A/WSN/
33; and full-length GP0 and the processed GP2 subunit for EBOV and MARV) (H and J) as prey via western blot. Data are representative of two independent
experiments.
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teins or genome, but rather renders the particles themselves
noninfectious, due in part to a defect in their ability to attach
to permissive host cells.
ERGIC-53 Traffics to Sites of JUNV Assembly and Is
Incorporated into Virions
Based on our finding that ERGIC-53 was detectable in concen-
trated supernatant preparations from JUNV C#1-infected cells
(Figure 4D), we hypothesized that ERGIC-53 might be packaged
into viral particles. We first addressed whether ERGIC-53 traf-
ficking was altered during infection by surface labeling cells
with antibodies specific for JUNV C#1 GP and ERGIC-53. We
observed discrete JUNV C#1 GP puncta of 200–400 nm at
the plasma membrane that we suggest are putative sites of viralCell Host &assembly and budding (Figure 5B). Strikingly, ERGIC-53 formed
puncta of the same size, shape, and position as GP (Figure 5B).
In contrast, ERGIC-53 was not detectable at the plasma mem-
brane of uninfected cells (Figure 5B). This altered trafficking is
specific, as calreticulin (CRT), another Ca2+-binding lectin of
the exocytic pathway, did not similarly redistribute to the plasma
membrane following infection (Figure 5C). The intracellular distri-
bution of ERGIC-53 did not change between mock- or JUNV
C#1-infected cells (Figure 5A). We next captured JUNV particles
using an anti-GPC/GP1 antibody and found that ERGIC-53
was detectable in JUNV particles via western blot (Figure 5D).
ERGIC-53 also colocalized with JUNV NP in viral particles
adhered onto coverslips (Figure S5). Thus, during arenavirus
infection, ERGIC-53 traffics to sites of viral assembly and
budding and is incorporated into virions.Microbe 14, 522–534, November 13, 2013 ª2013 Elsevier Inc. 527
Figure 4. Loss of ERGIC-53 Function Does
Not Inhibit the Formation of GP-Containing
Arenavirus Particles, but Instead Renders
Them Noninfectious
(AandB)TheER-restricted,DNERGIC-53doesnot
impair trafficking of JUNV C#1 GP to the plasma
membrane. HEK293T cells were transfected with a
plasmid expressing WT or DN ERGIC-53, then
inoculated 24 hr later with JUNV Candid #1 or not
(mock), andcollected72hr later to visualize internal
rERGIC-53 and surface JUNV GP staining via
confocal immunofluorescence microscopy (GP,
green; Myc-ERGIC-53, red) (A) or fluorescence-
activated cell sorting (FACS) (B). In (B), the histo-
grams are gated on Myc-positive cells and show
thepercentageof transfectedcellswithGPstaining
(gray, mock infected; white, JUNV C#1 infected).
The median fluorescence intensity (MFI) is re-
ported. Scale bars = 20 mm. Surface expression of
hTfR1 is not altered by DN ERGIC-53 (Figure S4).
(C) The DN ERGIC-53 mutant does not impair
proteolytic processing of JUNV GPC or the
incorporation of GP species into VLPs. HEK293T
cells were transfected with a plasmid expressing
WT or DN ERGIC-53, then 24 hr later with plas-
mids encoding the JUNV Z and XJ GPC proteins,
respectively, to permit the formation of VLPs.
Cells and supernatants (concentrated via ultra-
centrifugation through sucrose) were screened for
the presence of various GP species (the C-termi-
nally FLAG-tagged precursor GPC or proteolyti-
cally processed GP2) or actin via western blot.
The data are representative of two independent
experiments.
(D–G) JUNV C#1 generates GP-containing virus
particles that are noninfectious in ERGIC-53 null
cell lines. B cells derived from LMAN1+/+ (2829-D)
and LMAN1/ (CRC-78) individuals were chal-
lenged with JUNV C#1 or not, and supernatants
from these cells were concentrated through
sucrose and screened for viral proteins (GP1, NP,
and Z), ERGIC-53, or actin via western blot (D),
JUNV C#1 PFU via plaque assay (E), the ratio of
S segment genomic RNA copies, as measured by
quantitative RT-PCR, to pfu (F), or attachment
to host cells (G). All values are reported relative to
the LMAN1+/+ particles. Statistics are not shown
because the values in (D)–(G) were derived from
the same individual preparation of either
LMAN1+/+- or LMAN1/-derived viral particles.
For the attachment assay, virions were allowed to
bind to cells at 4C for 1.5 hr. Following washes
to remove unbound particles, bound virus was
enumerated on the basis of viral S segment
genomic RNA copies detected via quantitative
RT-PCR. The data in (D)–(F) are representative of
two independent experiments.
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RegionofERGIC-53’sCarbohydrateRecognitionDomain
and Occurs Independently of ERGIC-53’s Ability to
Oligomerize, Traffic, or Bind Mannose, MCFD2, or Ca2+
To determine the molecular basis for ERGIC-53’s association
with viral GPs, we screened a panel of ERGIC-53 mutants
(described in detail in Figure S6 and in Zheng et al.,
2010), for their ability to associate with the JUNV C#1 GP. As528 Cell Host & Microbe 14, 522–534, November 13, 2013 ª2013 Elsshown in Figure 6, of the 11 mutants screened, only the
DCRD mutant displayed a defect in binding to JUNV C#1 GP.
Interestingly, despite the requirement of the carbohydrate
recognition domain (CRD) for binding, the association of
ERGIC-53 with JUNV C#1 GP does not appear to be lectin
mediated, as mutations that disrupt ERGIC-53’s ability to
bind mannose (N156A, D181A, Db2, Db3, and Db4) do
not disrupt its interaction with JUNV C#1 GP. Likewise, theevier Inc.
Figure 5. ERGIC-53 Traffics to Sites of Arenavirus Budding and Is
Incorporated into Virions
(A–C) ERGIC-53 traffics to sites of arenavirus budding. JUNV C#1- or mock-
infected HEK293T cells were screened for internal expression of JUNV GPC/
GP1 and ERGIC-53 (A), surface expression of JUNV GPC/GP1 and ERGIC-53
(B), or, as a control, surface expression of JUNV GPC/GP1 and CRT (C) via
confocal microscopy. Scale bars = 10 mm (white), 20 mm (red), and 300 nm
(yellow).
(D) ERGIC-53 is a component of arenavirus particles. An anti-GP1 antibody
was used to immunoprecipitate viral particles from supernatants of JUNV-
infected or mock-infected Vero E6 cells. An irrelevant, species-matched
antibody was also used for immunoprecipitation from the JUNV-infected
supernatants. Cell lysates and immunoprecipitated protein fractions were
screened for viral proteins (GP1, NP, and Z) and ERGIC-53 via western blot
under nonreducing conditions. Data are representative of two independent
experiments. ERGIC-53 was also detectable in JUNV C#1 particles via
confocal microscopy (Figure S5).
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Cell Host &association does not appear to require Ca2+ binding (N156A
and D181A), oligomerization (DHM), the helix domain (DHelix),
or the association of MCFD2 (Db1, Db2, Db3, Db4, and
DHM). The DHM and DN ERGIC-53 (KKAA) results also suggest
that trafficking beyond the ER is not required for the interaction.
Finally, the DCRD, Db4, and DHelix results indicate that the GP-
interacting domain on ERGIC-53 lies within the C-terminal 185
amino acids of the CRD (residues 84–269).
DISCUSSION
Arenaviruses and hantaviruses are significant human pathogens
for which FDA-approved vaccines or effective antivirals do not
exist. Their proteomes consist of only four proteins. While
functional roles have been defined for each viral protein, their
interactions with host proteins, and the importance of these in-
teractions for viral replication and disease pathogenesis, remain
largely unknown. In the current study, we addressed this defi-
ciency by providing a comprehensive viral GP-human protein
interactome map using GPs encoded by a representative arena-
virus and hantavirus. We identified ERGIC-53 as a potential
antiviral target based upon its ability to associate with GPs
encoded by several families of pathogenic RNA viruses and its
clear role in the propagation of arenaviruses, coronaviruses,
and filoviruses. We demonstrate that ERGIC-53 is required not
for the formation of GP-containing arenavirus particles, but
rather for their infectiousness. We also show that ERGIC-53 traf-
fics to sites of arenavirus budding and is incorporated into
virions. Finally, we provide insight into the molecular basis for
the GP-ERGIC-53 interaction by showing that the C-terminal re-
gion of ERGIC-53’s CRD is required for the interaction indepen-
dent of ERGIC’s ability to oligomerize, traffic, or bind mannose,
MCFD2, or Ca2+.
ERGIC-53 is a nonglycosylated, hexameric type I integral
membrane protein that functions as a cargo receptor for soluble
glycoproteins within the early exocytic pathway. Its lumenal
domain contains a CRD with homology to leguminous lectins
and mammalian galectins; it selectively binds to high-mannose
glycans in a pH- and Ca2+-dependent manner (Appenzeller-Her-
zog et al., 2004; Appenzeller et al., 1999; Itin et al., 1996). Only
five glycoproteins—FV and FVIII (Moussalli et al., 1999; Nichols
et al., 1998), the cathepsins C and Z (Appenzeller et al., 1999;
Vollenweider et al., 1998), and alpha-1 antitrypsin (Nyfeler
et al., 2008)—have been shown to require ERGIC-53 for their
efficient anterograde trafficking. Typically, ERGIC-53 captures
its cargo proteins in the ER via its lectin activity and releases
them in the ERGIC, presumably due to the lower pH of this
compartment (Appenzeller-Herzog et al., 2004; Appenzeller
et al., 1999). In the case of FV and FVIII, MCFD2 is also required
for the trafficking of these proteins independent of ERGIC-53
(Zhang et al., 2003). Because ERGIC-53 and MCFD2 directly
interact, it has been suggested that they form a mature cargo
receptor required for efficient FV/FVIII trafficking (Nyfeler et al.,
2006; Zhang et al., 2005). Importantly, while loss of ERGIC-53
expression or function impairs movement of its specific ligands,
the overall architecture of the exocytic pathway is maintained,
and major glycoproteins still traffic normally (Mitrovic et al.,
2008; Nyfeler et al., 2006; Vollenweider et al., 1998). Indeed,
humans with homozygous null mutations in ERGIC-53 orMicrobe 14, 522–534, November 13, 2013 ª2013 Elsevier Inc. 529
Figure 6. The C-Terminal Region of ERGIC-53’s CRD Is Required for the ERGIC-53-JUNV GP Interaction
(A) Depiction of ERGIC-53 mutants used in this study. SS, signal sequence; F, FLAG epitope tag; TM, transmembrane. See Figure S6 for a detailed description of
each mutant.
(B) HEK293T cells were cotransfected with the BirA plasmid, a plasmid encoding JUNV C#1 GP with a C-terminal HA tag and BAP, and a plasmid encoding the
indicated ERGIC-53 mutants with an N-terminal FLAG tag. JUNV C#1 GP species (GPC and GP2) were affinity purified as bait from cell lysates. Input lysates and
captured bead fractions were screened for ERGIC-53 (prey) and, as a control, CRT (prey) via western blot. The data are representative of two independent
experiments.
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moderate bleeding symptoms due to reduced levels of circu-
lating FV/FVIII (5%–30% of normal) —are generally healthy
and lead normal lives, provided they receive FV/FVIII supple-
mentation following trauma (Khoriaty et al., 2012). These obser-
vations clearly suggest that ERGIC-53 is dispensable in humans
and therefore represents a viable antiviral target.
Our studies demonstrate that ERGIC-53 associates with a
class of pathogen-derived ligands, specifically GPs encoded by
arenaviruses, hantaviruses, coronaviruses, orthomyxoviruses,
and filoviruses (Figures 1, 3G–3J, S1E–S1I, and data not shown).
We show that, with the exception of the hantavirus GPs,
ERGIC-53 preferentially interacts with the uncleaved, precursor
GP, but not the proteolytically processed GP subunits (Figures
1I–1K, 3H, 3J, S1F–S1H, and data not shown). In the case of
the arenaviruses, this finding strongly suggests that the interac-
tion takes place in the ER and/or ERGIC, prior to proteolytic
cleavage of GPC into GP1/GP2 by the SKI-1/SP1 protease,
which is thought to occur in the Golgi (Lenz et al., 2001; Wright
et al., 1990). Indeed, imaging of JUNV C#1-infected cells
revealed that GP and ERGIC-53 both concentrate in the
ERGIC (Figures 1L and 5A). It was recently reported that the
HIV glycoprotein Env can also associate with ERGIC-53 (Ja¨ger
et al., 2012).
Based on previous studies, we initially hypothesized that the
ERGIC-53-GP interaction would be mediated by ERGIC-53’s
CRD binding to one or more high-mannose glycans on the viral
GPs. Our results demonstrate that while ERGIC-53’s CRD is
indeed critical for the interaction, its lectin- and Ca2+-binding
functions are completely dispensable (Figures 6 and S6).
Consistent with this claim, we also found the interaction to be
unaffected by competition with free mannose, manipulation of
Ca2+, changes in pH (as low as 5.0), or deglycosylation of the
JUNV or ANDV GP (data not shown). In summary, our studies
reveal that the molecular basis for ERGIC-53’s interaction with
JUNV GP is different from any of its previously characterized530 Cell Host & Microbe 14, 522–534, November 13, 2013 ª2013 Elspartners; only the C-terminal region of ERGIC-53’s CRD (resi-
dues 84–269) is critical for the interaction, whereas ERGIC-
53’s ability to oligomerize, traffic, or bind mannose, Ca2+, or
MCFD2 are not.
Movement of ERGIC-53 within the exocytic pathway is
controlled by at least three targeting determinants that work in
concert with two types of vesicular coats (COPII and COPI) to
mediate ER retention, ER exit, and retrieval from post-ER com-
partments (Hauri et al., 2000; Nufer et al., 2003). ERGIC-53 pref-
erentially accumulates in the ERGIC and recycles between this
compartment and the ER (Ben-Tekaya et al., 2005; Klumperman
et al., 1998). Under normal conditions, ERGIC-53 does not
appear to traffic beyond the cis-Golgi. However, following its
overexpression via plasmid, ERGIC-53 can traffic to the plasma
membrane, presumably due to saturation of COPI (Kappeler
et al., 1994). JUNV C#1 infection induces a striking redistribution
of a portion of the intracellular pool of ERGIC-53 to the plasma
membrane, where it strongly colocalizes with GP at putative
sites of viral assembly and budding (Figure 5B). Furthermore,
ERGIC-53 is packaged into arenavirus particles (Figures 5D
and S5), which may indicate that it is required for virion structure
and function.
The mechanism by which ERGIC-53 traffics to the plasma
membrane during JUNV C#1 infection is unclear, but one pos-
sibility is that ERGIC-53 expression increases during JUNV
infection and that saturation of COPI allows ERGIC-53 to traffic,
perhaps independent of its interaction with JUNV GP, beyond
the ERGIC and cis-Golgi to reach the plasma membrane. In
support of this idea, infection with the related arenavirus
LCMV triggers the activating transcription factor 6 (ATF6) arm
of the unfolded protein response (UPR) (Pasqual et al., 2011),
which is known to increase ERGIC-53 expression (Nyfeler
et al., 2003). Indeed, LCMV infection of nonhuman primates
results in increased transcription of ERGIC-53 (Djavani et al.,
2009). Alternatively, it is also possible that JUNV GP functions
as a cargo receptor to facilitate the movement of ERGIC-53evier Inc.
Figure 7. Proposed Model Depicting the
Role of ERGIC-53 in JUNV Propagation
Under WT conditions (top half of left cell), the
arenavirus GP undergoes a series of maturation
steps within the early exocytic pathway (1),
including proteolytic cleavage and trafficking to
the plasma membrane, where it is incorporated
into newly forming viral particles (2) that bud out of
the cell (3). The GP on newly formed particles then
attaches to its cellular receptor (4), which permits
endocytic uptake of particles into endosomes (5),
where low pH leads to GP2-mediated fusion of the
viral and endosomal membranes and, ultimately,
release of viral genome into the cytoplasm (6). In
the absence of ERGIC-53 (null) or in the presence
of the ER-restricted, DN ERGIC-53 (DN) (bottom
half of left cell), GP is still proteolytically pro-
cessed, trafficked to the plasma membrane, and
incorporated, along with other viral structural
proteins and viral genome, into budding particles
(1–3). These particles, however, lack ERGIC-53
and are defective in their ability to attach to host
cells (4). They may have deficiencies in other early
replication events (5 and 6) as well.
Cell Host & Microbe
ERGIC-53 Is Required for Virion Infectivitybeyond the ERGIC and cis-Golgi to sites of viral assembly and
budding.
How does ERGIC-53 impact arenavirus replication? We
initially hypothesized that ERGIC-53 was acting as a bona fide
cargo receptor required for the anterograde movement of GP
out of the ER and ultimately to the plasma membrane. This
idea proved incorrect, as expression of the ER-restricted, DN
ERGIC-53 mutant had no impact on the ability of GP to reach
the plasma membrane (Figures 4A and 4B). Likewise, there
was no disruption of either the proteolytic processing of GPC
into GP1/GP2 or the ability of these GP species to be incorpo-
rated into VLPs (Figure 4C). Additionally, the DN ERGIC-53
mutant had no impact on the ability of WT JUNV C#1 particles
to enter cells (Figures 4A and 4B) or on the level of expression
of hTfR1 at the plasma membrane (Figure S4). To formally test
whether ERGIC-53 is required for the release of viral particles,
we challenged normal or ERGIC-53 null cell lines with JUNV
C#1 and found similar quantities of viral particles in the superna-
tants from each cell line (Figure 4D). However, despite equivalent
particle release, the null cell-derived particles were10-fold less
infectious (Figure 4E), demonstrating that ERGIC-53 is essential
for the infectivity of JUNV C#1 particles. Therefore, in the
absence of ERGIC-53, arenavirus particles are produced in
normal quantities but are defective in the early phase of replica-
tion. Our results suggest that this defect minimally exists at the
level of virus attachment to the host cell (Figure 4G). It is possible
that this defect may also impair other steps of viral entry, such as
endocytic uptake of particles into host cells and/or fusion and
release of genome into the cytoplasm (see Figure 7 for our pro-
posed model).Cell Host & Microbe 14, 522–534, NHow does ERGIC-53 mechanistically
impact the infectiousness of arenavirus
particles? ERGIC-53 itself may be a crit-
ical structural component of the virion,
perhaps by acting as a coreceptorrequired for virion attachment to host cells. Direct support for
this idea includes our finding that ERGIC-53 is a component of
virions (Figures 5D and S5) and that virions lacking ERGIC-53
are defective (Figures 4D–4G). Additionally, less infectious
virus was produced in our challenge studies featuring the ER-
restricted, DN ERGIC-53 mutant (Figures 2C, 2D, 3B, S2C,
S2D, and S3B) or ERGIC-53 siRNA (Figures 2A and S2A).
Conversely, overexpression of WT ERGIC-53 leads to increased
trafficking of ERGIC-53 to the plasma membrane (Kappeler
et al., 1994), which could lead to more ERGIC-53 being incorpo-
rated into particles and explain the increased release of infec-
tious virus seen under these conditions (Figures 2B and S2B).
Alternatively, ERGIC-53 could be required to traffic and/or recruit
cellular proteins that are critically required for virion structure and
function or for the proper maturation of the arenavirus GP (e.g.,
glycan maturation or other posttranslational modifications).
The protein partners of arenavirus and hantavirus GPs iden-
tified in this study help advance our understanding of how
these viruses interact with host cell machinery to facilitate GP
biogenesis and other aspects of the viral lifecycle. As the
GPs themselves are likely to be highly multifunctional due to
the small size of their respective proteomes, the identified part-
ners may also help elucidate additional functions for each GP.
Each partner represents a candidate target for future antiviral
screening. Indeed, four additional proteins identified in our
study—stromal cell derived factor 4 (SDF4), archain 1
(ARCN1), coatomer protein complex subunit alpha (COPA),
and renin receptor (ATP6AP2)—were recently shown to be
required for LCMV and VSV replication (Panda et al., 2011).
These examples clearly highlight the feasibility and utility ofovember 13, 2013 ª2013 Elsevier Inc. 531
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viral targets.
In conclusion, ERGIC-53 represents a potential antiviral target
because of its clearly demonstrated importance for the replica-
tion of pathogenic arenaviruses, coronaviruses, and filoviruses
and the fact that loss of this protein or its function is well tolerated
in humans (Khoriaty et al., 2012). Furthermore, in the case of the
arenaviruses, targeting ERGIC-53 function with an antiviral could
be expected to set up an ongoing immunizing therapy, as defec-
tive, but presumably immunogenic, viral particles would be
released during the course of treatment. While ERGIC-53 repre-
sents a potential broad-spectrum antiviral target for arenavi-
ruses, coronaviruses, and filoviruses, it may also be required
for additional human pathogens, such as the New World hanta-
viruses, orthomyxoviruses, or retroviruses, based upon its
conserved interaction with their GPs (Figures 1D, 1E, 3I, 3J,
and S1I) (Ja¨ger et al., 2012), or for DNA viruses, based on the
finding that a murine gamma herpes virus was negatively
impacted by silencing of ERGIC-53 (Mages et al., 2008). Based
on our finding that JUNV propagation is impaired in cells from
ERGIC-53 null individuals, future studies should also address
whether exposure to rodent-borne viruses, such as the arenavi-
ruses, has exerted a selective pressure to maintain ERGIC-53
mutations within the human population as a means to confer
resistance to infection. Additionally, while bleeding is not a major
cause of morbidity or mortality during arenavirus or hantavirus
infection, it is interesting to consider that viral GPs, by interacting
with ERGIC-53, may disrupt ERGIC-53’s normal cargo receptor
function for FV and FVIII, contributing to some of the hemorrhag-
ic manifestations seen following infection with these viruses,
which can include deficiencies in the levels and/or activity of
circulating FV or FVIII (Lee, 1987; Lee et al., 1989; Schwarz
et al., 1972). The interaction of ERGIC-53 with the filovirus GPs
is particularly intriguing, considering the prominent coagulation
abnormalities observed during human infection (Feldmann and
Geisbert, 2011). Finally, our studies and others (Gonzalez-Begne
et al., 2009) have shown that ERGIC-53 is actively secreted from
cells in viral particles and/or cellular exosomes and strongly
suggest that it has important roles outside of its normal distribu-
tion within the exocytic pathway, perhaps outside of the cell
where, in the case of arenaviruses, coronaviruses, and filovi-
ruses, it may influence the endocytic pathway-driven process
of viral entry.
EXPERIMENTAL PROCEDURES
Cells, Viruses, Antibodies, Plasmids, siRNAs, and Transfections
A full description of the cells (human embryonic kidney 293T [HEK293T] cells,
Vero E6 cells, and B lymphoblastoid cells from either normal or ERGIC-53 null
individuals), viruses (DANV, JUNVC#1, and VSVDG), antibodies, siRNAs, plas-
mids, and transfection procedures used can be found in the Supplemental
Experimental Procedures.
Affinity Purification, Immunoprecipitation, Mass Spectrometry,
Virus and VLP Concentration, and Western Blot
To affinity purify viral GPs for the identification of human protein partners
via mass spectrometry or validation of protein partners via western blot,
HEK293T cells were cotransfected with a plasmid that encodes each respec-
tive viral GP with a C-terminal HA epitope tag and a biotin acceptor peptide
(BAP) as well as a second plasmid that encodes the bacterial biotin ligase
BirA to facilitate biotinylation of the viral GPs. After 2 days, biotinylated GPs532 Cell Host & Microbe 14, 522–534, November 13, 2013 ª2013 Elsand associated host proteins were affinity purified from whole-cell lysates
using magnetic streptavidin beads and separated on polyacrylamide gels for
either western blot analysis to confirm bait and prey purification or Coomassie
staining for mass spectrometry analysis. To determine the identity of cellular
proteins captured, each Coomassie-stained gel lane was cut into sections
for in-gel, tryptic digestion, and mass spectrometry analysis.
Immunoprecipitation of viral GPs or ERGIC-53 was accomplished by incu-
bating clarified whole-cell protein lysates with antibodies specific for each
respective protein followed by magnetic protein G beads. To purify intact
JUNV C#1 particles, supernatants were collected at 72 hr postinoculation,
clarified, and incubated with either an anti-GP antibody or an isotype control
antibody followed by magnetic protein G beads. Immunopurified proteins or
viral particles were then washed, eluted from beads, and electrophoresed
on polyacrylamide gels for western blot analysis.
JUNV C#1 virions and VLPs were concentrated via ultracentrifugation
through a 20% layer of sucrose.
For western blot analysis, protein lysates were separated by SDS-PAGE
using Novex 4%–20% Tris-Glycine polyacrylamide gels. Protein transfer to
nitrocellulose membranes was accomplished using the iBlot Gel Transfer
Device and iBlot Transfer Stack nitrocellulose membranes from Invitrogen.
Proteins were detected using either chemiluminescence or an Odyssey
Infrared Imaging System (LI-COR Biosciences).
Full details regarding these approaches are described in the Supplemental
Experimental Procedures.
Confocal Immunofluorescence Microscopy
A Zeiss LSM 510 Laser Scanning Confocal Microscope was used to
visualize internal or surface expression of ERGIC-53, CRT, JUNV NP, and/or
JUNV GP in cells or virions. Colocalization analysis was done using the Zeiss
AIM software package as described in the Supplemental Experimental
Procedures.
Flow Cytometry
An LSRII (BD Biosciences) was used to enumerate the frequency and intensity
of JUNV GP or hTfR1 staining at the plasma membrane or Myc-tagged WT
and/or DN ERGIC-53 internally in HEK293T cells, as described in the Supple-
mental Experimental Procedures.
Viral Challenge Assays
Viral challenge assays were performed to evaluate how various manipulations
of ERGIC-53 (siRNA silencing of ERGIC-53, overexpression of WT ERGIC-53,
expression of DN ERGIC-53, or loss of ERGIC-53 expression due to null
mutation of LMAN1) would influence the release of infectious JUNV C#1,
DANV, or VSVDG (pseudotyped with VSV G, JUNV XJ GP, SARS CoV S, or
EBOV GP). At each time point examined in the various assays, supernatants
and cells were collected (from each replicate well) to measure infectious virus
or protein expression levels, respectively. Infectious virus loadwas determined
via plaque assay for JUNV C#1 and DANV, while GFP-positive foci were
enumerated via focus assay for VSVDG; differences were determined using
the unpaired Student’s t test. Quantitative RT-PCR was used to determine
copy number of JUNV C#1 S segment genomic viral RNAs. Virus attachment
to cells was determined through a virus-cell binding assay. A full description of
each challenge assay can be found in the Supplemental Experimental
Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and one table and can be found with this article online at http://
dx.doi.org/10.1016/j.chom.2013.10.010.
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